Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycy

Protagonist Therapeutics NASDAQ: PTGX said the U.S. Food and Drug Administration has approved rusfer

The FDA approved Takeda's MIMRYLO to treat erythrocytosis in adults with polycythemia vera, offe

HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) wit

J&J's portfolio primarily includes small biotech and medtech companies. Its largest investment is in

MIMRYLO™ is the First and Only Hepcidin Mimetic Peptide Therapy Approved for the Treatment of Erythr

Bamco Inc. NY bought a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) in the s

NEWARK, CA / ACCESS Newswire / August 18, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today

BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperfo

Small-cap stocks are surging, but how you own them matters more than most investors realize.

Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA

Protagonist Therapeutics (PTGX) maintains a "Strong Buy" rating, driven by FDA approval of ICOTYDE f

PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-s

Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) w

Wedbush analyst Yun Zhong maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and

Wall Street analysts upgraded PTGX, LECO, and JHX. See analyst ratings and price targets for these s

Goldman Sachs analyst Richard Law upgrades Protagonist Therapeutics (NASDAQ:PTGX) from Neutral t

Vanguard's tech-heavy portfolio delivered stronger five-year returns despite higher volatility, whil

Protagonist Therapeutics (PTGX) shares have started gaining and might continue moving higher in the

Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight

Protagonist Therapeutics (PTGX) came out with quarterly earnings of $2.29 per share, beating the Zac

Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly earnings of $2.29 per share which beat the

ICOTYDE™ First Full Quarter of Commercial Sales with Strong Early Adoption Rusfertide NDA under Prio

NEWARK, CA / ACCESS Newswire / August 4, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today r

Bank of New York Mellon Corp lowered its holdings in shares of Protagonist Therapeutics, Inc. (NASDA

Fifth Third Bancorp grew its position in Protagonist Therapeutics, Inc. (NASDAQ: PTGX) by 3,937.3% d

NEWARK, CA / ACCESS Newswire / July 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today re

Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight

SNDK, PTGX and LION made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13th, 202

FOX, LION, EDRY, PTGX and SPH have been added to the Zacks Rank #1 (Strong Buy) List on July 13th, 2

PTGX, DHX, COOK, XYZ and ARLP have been added to the Zacks Rank #1 (Strong Buy) List on July 9, 2026

Protagonist Therapeutics (PTGX) witnessed a jump in share price last session on above-average tradin

Protagonist shares rise as rusfertide nears an FDA decision and Icotyde adds milestone payments, roy

Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) w

Silence Therapeutics ($SLN) stock surges as Cantor predicts key August Phase 2 data will be a major

AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its

Silence Therapeutics says SANRECO data show sustained polycythemia vera benefits as analysts weigh d

Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that

Citizens analyst Jonathan Wolleben maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Market

Wedbush analyst Yun Zhong maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and

Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly earnings of $0.05 per share which beat the

By exercising its opt-out right during the contractual opt-out period, Protagonist becomes eligible

Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) w

Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, includi

Clear Street analyst Kaveri Pohlman maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy a

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and

Leerink Partners analyst Faisal Khurshid maintains Protagonist Therapeutics (NASDAQ:PTGX) with a

Citigroup analyst Geoff Meacham maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and r

Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight

FDA approves Icotyde, a once-daily psoriasis pill from Johnson & Johnson, sparking new competiti